The SVR rate was 29.4%. assayed at the end of this treatment period Eicosadienoic acid and again at 24 wk later on. A biochemical response was determined by a normalization of SGPT at the end of the treatment or during follow up. The end of treatment response was defined by a HDV-RNA bad status. A sustained virological response was defined by undetectable serum HDV-RNA at six months after the end of treatment. RESULTS: Among the 277 individuals enrolled in our present study, 238 completed a course of peg-interferon therapy of which 180 (75.6%) were male and 58 (24.4%) woman. Biochemical responses were accomplished in 122/238 (51.3%) individuals. End of treatment reactions were accomplished in 71/238 (29.8%) instances. A SVR was accomplished in 70 Gja4 of these individuals (29.4%). A strong association was found between the SVR and the end of treatment reactions (= 0.001), biochemical reactions (= 0.001) and the degree of fibrosis (= 0.002). Summary: Peg-interferon therapy Eicosadienoic acid can induce remission in nearly one third of individuals harboring HDV. value of 0.05 was considered statistically significant. All data were processed on SPSS Version 16. RESULTS Of the 277 individuals enrolled in this study, 238 completed the course of interferon therapy. Among the remaining 39 individuals, 31 were excluded from the study because of minimal (stage 0 and 1) fibrosis and eight individuals were dropped because of interferon-induced complications early in study period. Of the remaining 238 individuals who were analyzed, 180 (75.6%) were male and 58 (24.4%) woman. The mean age was 29.6 8.5 years, hemoglobin (g/dL) was 11.49 2.45, platelet count (103/mm3) was 145.6 14.3, and SGPT (IU/L) was 134.18 14.3. Hepatitis B DNA level (IU/mL) 155.1 70.1. Fibrosis stage 2 was present in 172 (72.3%), stage 3 in 44 (18.5%) and stage 4 in 22 (9.2%) individuals. A biochemical response was accomplished in 122/238 (51.3%) individuals and not Eicosadienoic acid in 116 (48.7%) instances. End of treatment reactions were accomplished in 71/238(29.8%) instances and not in 167 (70.2%) individuals. SVR was accomplished in 70 (29.4%) individuals. The baseline characteristics of the individuals in the study cohort are outlined in Table ?Table1.1. A strong association was found between SVR and end of treatment response (= 0.001) while 70/71 (98.5%) individuals who obtained an end of treatment response also accomplished an SVR. The association between an SVR and the stage of fibrosis was also significant (= 0.002) while 39/172 (22.6%) individuals with fibrosis stage 2, 18/44 (40.9%) individuals with fibrosis stage 3 and 13/22 (59%) individuals with fibrosis stage 4 accomplished SVR, and with the biochemical response (= 0.001) while 60/122 (49.1%) of such individuals also achieved SVR. Table ?Table22 shows connection of end of treatment response, biochemical response and stage of fibrosis with SVR. ROC curve comparing the end of treatment response, biochemical response, stage of fibrosis and SVR is definitely demonstrated in Number ?Number1.1. The end of treatment response was found to be predictive of an SVR having a level of sensitivity of 98%, specificity of 94%, positive predictive value (PPV) of 94.45, and negative predictive value (NPV) of 98% (= 0.001). A biochemical response was also predictive of an SVR having a level of sensitivity of 85.7%, specificity of 63.2%, PPV of 69.9% and NPV of 81.5% (= 0.001). The degree of fibrosis expected an SVR having a level of sensitivity of 44.3%, specificity of 46%, PPV of 45% and NPV of 45.3% (= 0.002). Table 1 Baseline characteristics of individuals (= 238) Continuous variables (imply SD)Age (yr)29 8.5Hemoglobin (g/dL)11.49 2.45The mean platelet count (103/mm3)145.6 14.3SGPT (IU/L)134.18 14.3Hepatitis B DNA level (IU/mL)155 103 70.1 103Categorical variable, Eicosadienoic acid frequency (%)SexMale180 (75.6)Female58 (24.4)Stage of fibrosisStage 2172 (72.3)Stage 344 (18.5)Stage 422 (9.2)Biochemical response122 (51.3)End of treatment71 (29.8)Sustained viral response70 (29.4) Open in a separate windowpane SGPT: Serum glutamic pyruvic transaminase. Open in a separate window Number 1 Receiver operating characteristic curve comparing end of treatment response, biochemical response, stage of fibrosis with sustained viral response. Receiver operating characteristic curve showing assessment between end of treatment response [area under curves (AUC) 0.997, 95% CI: 0.99-1.004], biochemical response (AUC 0.744, 95% CI: 0.67-0.81), stage of fibrosis (AUC 0.625, 95%.